Home

MARK G FOLETTA

CIK 1236389 · EVP & Chief Financial Officer · last filed 2026-08-04

MARK G FOLETTA is an EVP & Chief Financial Officer who has filed 130 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider sold $330.6K of DXCM on Aug 4, 2026. Across all open-market trades the lifetime net is −$8.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$6.39M

Companies

10

Total Filings

130

Lifetime Open-Market Net

-$8.49M

Filer Profile

Reported Address
2999 OLYMPUS BOULEVARD
SUITE 500
DALLAS, TX 75019
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DXCM Director 57,183 $86.62 $4.95M -$5.96M 39 2026-08-04
AMN Director 41,515 $34.56 $1.43M -$1.20M 21 2026-06-17
ENTA Director — $11.88 — $0 7 2026-03-13
Forte Biosciences, Inc. (TOCA) Delisted EVP & Chief Financial Officer 1,003 — — $71.5K 7 2019-10-04
Regulus Therapeutics Inc. (RGLS) Delisted Director 683 $8.16 $5.6K $76.4K 7 2017-12-06
AMN HEALTHCARE SERVICES INC (AHS) Delisted Director 5,532 — — $0 4 2016-04-22
BIOCEPT INC (BIOC) Delisted Interim CFO — $0.43 — $0 1 2015-09-02
AMBIT BIOSCIENCES CORP (AMBI) Delisted Director — $0.54 — $0 2 2014-11-12
AMYLIN PHARMACEUTICALS INC (AMLN) Delisted SVP, Chief Financial Officer 81,344 — — -$1.48M 25 2012-07-26
ANADYS PHARMACEUTICALS INC (ANDS) Delisted Director — — — $0 6 2011-05-27

Recent Filings

130 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-04 DXCM Sell (S) −4,000 -$330.6K EDGAR
2026-08-03 DXCM Notice (144) −2,000 -$170.6K EDGAR
2026-07-31 DXCM Notice (144) −2,000 -$160.0K EDGAR
2026-06-17 AMN Sell (S) −3,681 -$114.4K EDGAR
2026-06-17 DXCM Sell (S) −4,000 -$296.5K EDGAR
2026-06-15 DXCM Notice (144) −4,000 -$302.8K EDGAR
2026-06-15 AMN Notice (144) −3,681 -$114.1K EDGAR
2026-06-01 DXCM Grant (A) +6,331 $0 EDGAR
2026-05-11 DXCM Gift (G) — $0 EDGAR
2026-05-04 AMN Mixed +8,325 $0 EDGAR
Showing 1–10 of 130
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.